Pfizer (PFE) and Astellas (ALPMF) (ALPMY) announced Monday that the FDA has granted priority review for their marketing application, which seeks U.S. approval for their antibody drug conjugate, Padcev ...

The healthcare giant has been investing heavily in its future growth.

U.S. Food and Drug Administration "enforcement in the social media space has historically been somewhat limited, but recent ...

The FDA has scolded Pfizer over Facebook ads for the cancer drug Adcetris, accusing the Big Pharma of failing to adequately ...

AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE) both reported fourth quarter earnings in early February. AbbVie posted record net ...

In an Untitled Letter, regulators said Facebook promotions for Pfizer’s lymphoma therapy overstated its approved use and ...

Storm Therapeutics has closed a $56 million series C financing as the British biotech kicks off a phase 2 sarcoma trial of ...

Pfizer's oncology unit displays mixed Q1 trends as key drugs and biosimilars offset Ibrance declines ahead of earnings on May 5 ...

The healthcare stock looks ridiculously undervalued.

On the second trading day of the week, Pfizer ( PFE 2.62%) was a laggard on the stock exchange. An analyst reiterated his ...

Before deciding to walk away from the building, Pfizer tried to list nearly half of the 164,000-square-foot campus for ...

The news is the latest example of the biotech industry's struggles in the Bay Area.